An Open Label Phase 1 Study of Safety and Immunogenicity of JNJ-64041757, A Live Attenuated Listeria Monocytogenes Immunotherapy, in Subjects With Non-Small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 23 Jun 2017
At a glance
- Drugs ADU 214 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Janssen
- 16 Jun 2017 Planned End Date changed from 28 Nov 2018 to 6 Mar 2020.
- 16 Jun 2017 Planned primary completion date changed from 3 Apr 2017 to 6 Mar 2020.
- 10 Jun 2017 Biomarkers information updated